{Reference Type}: Journal Article {Title}: Baseline findings of a multicentric ambispective cohort study (2021-2022) among hospitalised mucormycosis patients in India. {Author}: Abdulkader RS;Ponnaiah M;Bhatnagar T;S D;Rozario AGA;K G;Mohan M;E M;Saravanakumar D;Moorthy A;Tyagi AK;Parmar BD;Devaraja K;Medikeri G;Ojah J;Srivastava K;K K;Das N;B N;Sharma P;Kumar Parida P;Kumar Saravanam P;Kulkarni P;S P;Patil S P;Kumar Bagla R;D R;S Melkundi R;S Satpute S;Narayanan S;Jahagirdar S;Dube S;Kumar Panigrahi S;Babu D S;Saini V;Singh Saxena R;Srivastava A;Chandra Baishya A;Garg A;Kumar Mishra A;Jyoti Talukdar A;Kankaria A;Karat A;Sundaresh Kumar A;Chug A;Vankundre A;Ramaswamy B;Mb B;R Jadav B;Dhiwakar M;Ghate G;Shah HV;Saha I;Sivapuram K;J Joshi K;Singh M;Chand Bairwa M;K D;K K;E M;Samagh N;Dinakaran N;Gupta N;Gupta N;M Nagarkar N;Solanki N;Kumar Panda P;Bachalli P;Shanbag R;Patil R;Kumar A R;Narayan Patil R;Thookkanaickenpalayam Vijayaraghavan R;Hanumantappa R;A R;Mandal SK;Kishve SP;Varghese Thomas S;Sarkar S;Thakur S;Patil S;Lakshmanan S;D Rao S;V S;Nayak T;Dixit UR;B U;Backiavathy V;Shenoy V;Hallur VK;Bhatnagar A;Murhekar MV; {Journal}: Mycology {Volume}: 15 {Issue}: 1 {Year}: 2024 暂无{DOI}: 10.1080/21501203.2023.2271928 {Abstract}: In India, the incidence of mucormycosis reached high levels during 2021-2022, coinciding with the COVID-19 pandemic. In response to this, we established a multicentric ambispective cohort of patients hospitalised with mucormycosis across India. In this paper, we report their baseline profile, clinical characteristics and outcomes at discharge. Patients hospitalized for mucormycosis during March-July 2021 were included. Mucormycosis was diagnosed based on mycological confirmation on direct microscopy (KOH/Calcofluor white stain), culture, histopathology, or supportive evidence from endoscopy or imaging. After consent, trained data collectors used medical records and telephonic interviews to capture data in a pre-tested structured questionnaire. At baseline, we recruited 686 patients from 26 study hospitals, of whom 72.3% were males, 78% had a prior history of diabetes, 53.2% had a history of corticosteroid treatment, and 80% were associated with COVID-19. Pain, numbness or swelling of the face were the commonest symptoms (73.3%). Liposomal Amphotericin B was the commonest drug formulation used (67.1%), and endoscopic sinus surgery was the most common surgical procedure (73.6%). At discharge, the disease was stable in 43.3%, in regression for 29.9% but 9.6% died during hospitalization. Among survivors, commonly reported disabilities included facial disfigurement (18.4%) and difficulties in chewing/swallowing (17.8%). Though the risk of mortality was only 1 in 10, the disability due to the disease was very high. This cohort study could enhance our understanding of the disease's clinical progression and help frame standard treatment guidelines.